Bausch + Lomb (BLCO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Bausch + Lomb (BLCO) reported $1.28 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 7.1%. EPS of $0.18 for the same period compares to $0.17 a year ago.

The reported revenue represents a surprise of -0.04% over the Zacks Consensus Estimate of $1.28 billion. With the consensus EPS estimate being $0.16, the EPS surprise was +12.5%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Bausch + Lomb performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Vision Care: $736 million compared to the $743.74 million average estimate based on three analysts. The reported number represents a change of +7.6% year over year.
• Revenues- Surgical: $215 million versus $214 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
• Revenues- Pharmaceuticals: $330 million compared to the $327.18 million average estimate based on three analysts. The reported number represents a change of +7.8% year over year.
• Revenues- Product sales: $1.28 billion versus $1.27 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.
• Revenues- Other revenues: $4 million versus the two-analyst average estimate of $5 million. The reported number represents a year-over-year change of 0%.

View all Key Company Metrics for Bausch + Lomb here>>>

Shares of Bausch + Lomb have returned +0.9% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Bausch + Lomb Corporation (BLCO): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research